Sarepta Therapeutics stock rose about 20% after releasing initial clinical data from two siRNA programs targeting rare neuromuscular diseases with no approved treatments: FSHD1 and DM1. Early Phase 1/2 results showed dose-dependent muscle targeting, biomarker improvements, and good tolerability, signaling potential despite the company's recent stock decline and challenges with its gene therapy ELEVIDYS. The programs use a targeted delivery method licensed from Arrowhead Pharmaceuticals, which earned Sarepta a $200 million milestone payment. While promising, these early results need further validation in larger trials, with more data expected later this year. Sarepta aims for profitability by 2026, backed by strong cash reserves, but the small patient populations and regulatory uncertainties pose risks.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Bitcoin price recently hit a strong resistance level at $65,600 but failed to break through, signaling a possible reversal. Short-term momentum is weakening, suggesting the price may decline unless a sudden surge occurs. Key support levels include th...
